Regulatory Support

Navigating Regulatory Complexity with Confidence

At ABX, our CDMO services go beyond development and manufacturing – we support our partners throughout the entire regulatory journey.

From clinical trials to marketing authorization, our team brings deep expertise to every step of the approval process.

Regulatory Expertise Across 42 Countries

With regulatory submissions in 42 countries across North- and South America, Europe and APEC we support over 87 marketing authorizations of our customers. In addition, we are building on our experiences with our own marketing authorization of Radelumin® in Europe, and therefore we are able to fully understand the regulatory needs of our customers and meet the regulatory requirements of various healthcare authorities.

With proven global experience in regulatory documentation, we help streamline submissions and accelerate your path to market.

Our Expertise. Your Success.

Extensive experience in navigating the unique regulatory requirements of radiopharmaceuticals and helping customers achieve successful regulatory submissions.

Proactive development of regulatory strategies to support efficient submissions, lifecycle management, and global market access.

Specialized CMC expertise supporting efficient regulatory submissions, successful authority interactions, and long-term compliance.

Extensive experience in supporting regulatory activities across international markets, with a strong understanding of regional requirements and regulatory expectations.

Proactive maintenance and periodical updates of CMC documentation, ensuring continued compliance with regulatory requirements. Support of customers with variation-specific documentation.

Preparation and coordination of responses to requests for further information and deficiency letters, ensuring timely and effective communication with competent authorities.

Regulatory support for technology transfer projects to external CMOs, ensuring regulatory alignment, compliant implementation of manufacturing changes, and a smooth transition into routine production.

Transforming Expertise into Regulatory Success

More than 20 years of experience turning scientific innovation into successful regulatory outcomes.

2003

Laying the Regulatory Foundation

Submission of our first DMF and ASMF, marking the beginning of our regulatory journey.
2013

Expand DMF submissions

Strengthen expertise through further DMF submissions to FDA. 
2018

Entering Clinical Development

Initiation of our first own Phase II clinical trial, advancing innovation toward patient care.
2019

Advancing Clinical Innovation

Launch of our first Phase III clinical trial, representing a major step toward commercialization.
2021

First Marketing Authorisation Achievement

National approval of Radelumin®, demonstrating our capability to successfully bring innovative products to market.
2023

Growing Across Europe

Successful completion of the Mutual Recognition Procedure (MRP) for Radelumin®, expanding access across European markets.
2025

Expanding into the UK

Successful completion of the UK marketing authorisation procedure for Radelumin®, further strengthening our international presence.
2026

Strengthening Our Global Reach

DMF submissions across multiple Asian markets, supporting international growth and broadened market access.

Our Expertise in CDMO / CMO Services

At ABX, we continuously advance the development of new radiopharmaceutical solutions – from the initial idea to clinical application. We combine scientific excellence with practical feasibility, turning innovative approaches into market-ready solutions.